MedTrace Logo

SPECTA: Screening Cancer Patients for Efficient Clinical Trial Access

NCT02834884 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 4975

Last updated 2026-06-24

No results posted yet for this study

Summary

SPECTA is a quality assured platform for collecting clinicopathologically annotated biological material, imaging data, operative images, environmental assessment, questionnaires as well as patient-reported outcomes from cancer patients to support biospecimen-based translational research and clinical cancer research, including biomarker discovery to improve the understanding of tumor biology and cancer patients care.

Conditions

  • All Tumor Types

Interventions

GENETIC

RP-1828 IMMUcan

WES, lcWGS and RNAseq, multiplex IF and IMC

GENETIC

RP-1759 AYA/TYA

WES, RNAseq and EPIC array

GENETIC

RP-1843 Arcagen

NGS panel

GENETIC

RP-1920 BioRadon

NGS panel

GENETIC

2148 MRD

ctDNA detection and WES

Sponsors & Collaborators

  • European Organisation for Research and Treatment of Cancer - EORTC

    lead NETWORK

Principal Investigators

  • Benjamin Besse, Pr. · European Organisation for Research and Treatment of Cancer - EORTC

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-05-03
Primary Completion
2022-08-29
Completion
2031-10-31

Countries

  • Austria
  • Belgium
  • Croatia
  • Cyprus
  • Czechia
  • Estonia
  • France
  • Germany
  • Greece
  • Italy
  • Lithuania
  • Netherlands
  • Poland
  • Portugal
  • Romania
  • Serbia
  • Slovenia
  • Spain
  • Switzerland
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02834884 on ClinicalTrials.gov